China (Mainland)
exporter High purity of Tenofovir Alafenamide Hemifumarate TAF Top quality of 1392275-56-7 CAS NO.1392275-56-7
- Min.Order: 1 Kilogram
- Payment Terms: L/C,D/A,D/P,T/T,Other
- Product Details
Keywords
- 1392275-56-7 exporter
- High purity of Tenofovir Alafenamide Hemifumarate TAF
- Top quality of 1392275-56-7
Quick Details
- ProName: exporter High purity of Tenofovir Alaf...
- CasNo: 1392275-56-7
- Molecular Formula: C21H29O5N6P·1/2(C4H4O4)
- Appearance: White to off white powder.
- Application: HIV, HBV
- DeliveryTime: 10 days after ordering
- PackAge: Two-layer LDPE bag and All Paper Barre...
- Port: Any port in China
- ProductionCapacity: 10 Metric Ton/Year
- Purity: 98.0%~102.0% (on the anhydrous basis)
- Storage: 2~8°C
- Transportation: as per request
- LimitNum: 1 Kilogram
Superiority
exporter High purity of Tenofovir Alafenamide Hemifumarate TAF Top quality of 1392275-56-7
Tenofovir Alafenamide fumaric acid is a reverse transcriptase inhibitor. Upon entry into liver cells, the drug can be hydrolyzed to tenofovir. Tenofovir is then phosphorylated by intracellular kinases to become pharmacologically active tenofovir diphosphate. Tenofovir diphosphate is integrated into viral DNA by HBV reverse transcriptase, which leads to the interruption of DNA chain synthesis and inhibits viral replication.
This drug is mainly used in adult chronic hepatitis B patients with active hepatitis B virus replication, continuously elevated transaminase, or liver histology showing active liver disease.
In a clinical trial numbered NCT01940341, 425 patients with chronic hepatitis B were randomly assigned to TAF and TDF for 48 weeks according to a computer-generated code. A control study was conducted between the two groups, in which TAF was given 25 mg once a day. The dose of TDF was 300 mg once a day, and the HBV DNA negative conversion rate and ALT recovery rate of TAF were better than THAT of TDF.
LONZEAL Pharmaceuticals was founded in 2006 and has become a leading manufacturing company covering finished formulation, active pharmaceutical ingredients and advanced intermediates, where ICH guidelines have been strictly applied in the whole chain of R&D, manufacturing process and quality management.
LONZEAL is taking attentiveness and profession to build high quality products, and contributing to health and beautiful life for everyone in the world. The products and manufacturing site of Lonzeal have been approved and inspected by stringent drug authorities such as USFDA, WHO, China NMPA, Brazil ANVISIA and India DCGI, based on which, we have been supplying to esteemed customers globally in the past 15 years with regulatory compliance and good quality.
We have manufacturing site located in Hebei National Biomedical Industrial Zone, FPPs and APIs R&D Center of in Shijiazhuang Hi-tech Development Park, and the commercial office in Beijing, China.
Our current main products cover anti-virus, anti-depression and anti-neuropathic pain areas. Lonzeal has become one of the key manufacturers in the global supply of anti-HIV drugs and is providing support to the treatment need of over 4 Million patients each year worldwide.
LONZEAL is taking attentiveness and profession to build high quality products, and contributing to health and beautiful life for everyone in the world. The products and manufacturing site of Lonzeal have been approved and inspected by stringent drug authorities such as USFDA, WHO, China NMPA, Brazil ANVISIA and India DCGI, based on which, we have been supplying to esteemed customers globally in the past 15 years with regulatory compliance and good quality.
We have manufacturing site located in Hebei National Biomedical Industrial Zone, FPPs and APIs R&D Center of in Shijiazhuang Hi-tech Development Park, and the commercial office in Beijing, China.
Our current main products cover anti-virus, anti-depression and anti-neuropathic pain areas. Lonzeal has become one of the key manufacturers in the global supply of anti-HIV drugs and is providing support to the treatment need of over 4 Million patients each year worldwide.
Details
An overview of the
Gilead's new drug, Vemlidy (Tenofovir alafialamine fumarate, 25mg, qD), was approved by the U.S. FDA to compensate for chronic hepatitis B virus infection in patients with liver disease. Vemlidy is an innovation of targeting drug tenofovir ago, with previous products 300 mg of Viread (tenofovir ester of fumaric acid salt, tenofovChemicalbookirdisoproxilfumarate), compared to only need less than one over ten of the dose can obtain similar antiviral activity. Clinical data showed that Vemlidy had better plasma stability and was able to deliver tenofovir to hepatocytes more effectively. Because of the lower dose, Vemlidy can improve the safety risk of kidney and bone in patients.
role
Tenofovir alafenamide (TAF), an oral nucleoside transcriptase inhibitor developed by Gilead, is another prodrug of tenofovir disoproxil fumarate (TDF), developed for hepatitis B virus infection (HBV) and acquired immune syndrome (HIV).
use
Tenofovir alafine fumarate can be used as a solvent, catalyst for alkylation, esterification and polymerization reactions. 99% of the products are mainly used in the medical field and 70% are mainly used in the electroplating industry, Chemicalbook industry. Nutritional drugs, combined with a low-protein diet, are the core drugs for the prevention and treatment of damage caused by protein metabolism disorder caused by chronic renal insufficiency, chronic renal insufficiency and wasting malnutrition.